Off-label use and promotion in the EU: risks and potential liability
This article was originally published in SRA
Liesbeth Weynants and Carla Schoonderbeek call for greater clarification and co-ordination of off-label requirements in the EU.
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.